How much does a box of Mobotinib cost?

Mobocertinib (Mobocertinib), also known as mobocertinib, is an innovative drug targeting non-small cell lung cancer with specific gene mutations. Mobotinib is an oral tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins).
Epidermal growth factor receptor (EGFR) is a transmembrane receptor that regulates signaling pathways in the control of cell proliferation. Mutations in these proteins have been linked to certain types of lung cancer, including non-small cell lung cancer (NSCLC). While most EGFR mutations associated with NSCLC include EGFRL858R point mutations or exon 19 deletions (called EGFR mutations), less common EGFR exon 20 insertion mutations have a particularly poor prognosis and are associated with resistance to standard targeted EGFR inhibitors.

Mobotinib is an EGFR inhibitor. It irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild-type EGFR protein, and exerts pharmacological effects on mutant variants at concentrations 1.5-10 times lower than wild-type protein.

There are related generic versions of Mobotinib available overseas. There are two generic versions of Mobotinib available overseas, one from Lucius Pharmaceuticals in Laos and Ziska Pharmaceuticals in Bangladesh. The specification of Mobotinib marketed by Ziska in Bangladesh is 40mg*60 tablets, and the price is about 3,600 yuan; the specification of Mobotinib marketed by Lucius Pharmaceuticals in Laos is 40mg*120 tablets, and the price is about 3,900 yuan. If the patient has more questions about Mobotinib, please consult a professional doctor.

Mobotinib has a good safety profile. Common adverse reactions include diarrhea, nausea, etc., but most are tolerated and controlled through appropriate management. In summary, mobotinib, as an innovative drug targeting NSCLC with EGFR ex20ins mutations, provides patients with a new treatment option.